Persistent Diarrhea Months After CAR-T Therapy: A Review of Delayed Enterocolitis Diagnosis and Treatment

Background
A review highlights immune effector cell-mediated enterocolitis (IEC-EC) as a consideration when persistent diarrhea and malabsorption develop months after chimeric antigen receptor T-cell (CAR-T) therapy. The paper brings together case series reported after treatment for blood cancers; it does not test diagnostic methods or treatment efficacy in a new clinical trial. The authors summarize the clinical presentation and diagnostic and treatment approaches for this rare but potentially life-threatening delayed complication.
CAR-T therapy makes a patient’s T cells express receptors that recognize specific antigens, enabling the cells to attack their targets. Unlike mild gastrointestinal symptoms in the acute period after infusion, IEC-EC can cause persistent inflammation in the small or large intestine. CAR-T cells have been identified in the intestinal mucosa in some cases, but the full disease mechanism remains unknown. The authors suggest that depletion of mucosal immune cells, immune dysregulation, and infection may all contribute.
Key findings
IEC-EC has been reported mainly after B-cell maturation antigen (BCMA)-targeted CAR-T therapy. In a cohort of 125 recipients of ciltacabtagene autoleucel cited in the review, 7 patients (5.6%) developed the condition. The abstract summarizes the frequency as “up to about 6%,” but this should not be interpreted as a pooled incidence across all CAR-T recipients. Cases have also been reported after CD19-targeted therapy, so IEC-EC is not limited to BCMA-targeted treatment.
The typical presentation is persistent, nonbloody watery diarrhea beginning 1–3 months after infusion. Malabsorption and weight loss may accompany it, and some patients have required prolonged parenteral nutrition. This is a typical onset window, not a criterion that limits diagnosis to that period.
Endoscopic findings range from normal-appearing mucosa to inflammation and ulceration. Tissue samples may show villous atrophy, increased intraepithelial lymphocytes, and apoptosis of intestinal crypt cells, but many findings overlap with those of other intestinal diseases. Small-bowel involvement, particularly in the duodenum, may be prominent. The authors therefore propose including upper gastrointestinal endoscopy and duodenal biopsy in the initial evaluation rather than concluding the assessment with colonoscopy alone.
Concurrent infection can complicate diagnosis. The review emphasizes conducting infection testing and treatment alongside endoscopic and histological evaluation, and considering IEC-EC if symptoms persist despite adequate anti-infective treatment. Because T-cell lymphoproliferative disorders can have overlapping clinical and histological findings, the authors also stress expert pathology review.
Implications and outlook
Supportive care and infection management are foundational, but responses to drug treatment are inconsistent. Even systemic corticosteroids, commonly used after infection has been ruled out or adequately treated, have had limited or short-lived effects. The inflammatory bowel disease drugs infliximab and vedolizumab have been reported to help some patients, but which drug to use first and the role of small-molecule drugs remain unclear.
Some IEC-EC case series cited in the review reported mortality of 33–37%. Causes of death included intestinal perforation, infection, and sepsis. These figures come from small groups of patients who developed enterocolitis; they do not represent the mortality risk for all CAR-T recipients.
The paper summarizes diagnostic and treatment approaches and proposes an algorithm to help avoid missing delayed enterocolitis. Without prospective trial data, current management relies heavily on case series, registry data, and expert opinion. Early recognition and multidisciplinary care may improve patient outcomes, but further research is needed to establish the optimal treatment sequence and predictors of response. The full review describes the clinical presentation and limitations of the evidence in detail.
BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionised the treatment of hematologic malignancies, and its use is expanding rapidly into numerous other disease states including autoimmune diseases. However, CAR-T therapy is associated with a spectrum of immune-related toxicities. In addition to the already well characterized cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, it has become apparent that rarely, CAR-T can cause gastrointestinal mucosal inflammation, termed immune effector cell-mediated enterocolitis (IEC-EC). AIMS: This state-of-the-art review highlights the CAR-T mechanism and details the epidemiology, pathophysiology, clinical manifestations, endoscopic and histopathologic features, and management of IEC-EC. METHODS: This review presents the current state of knowledge through a comprehensive and detailed synthesis of all case series reported in the literature to date. RESULTS: Occurring in up to approximately 6% of patients typically following B cell maturation antigen-targeted CAR-T therapy, IEC-EC presents with severe diarrhoea and malabsorption, responds poorly to treatment, and portends a dire prognosis. Multi-disciplinary management should centre on early diagnosis, supportive cares, assessment and treatment of infections, and step-up pharmacotherapy, often featuring biologics and small molecules drawn from the inflammatory bowel disease pharmacologic armamentarium. CONCLUSIONS: Clinicians should maintain a high degree of vigilance for IEC-EC in patients presenting with gastrointestinal symptoms following CAR-T treatment. Early recognition and multi-disciplinary treatment may improve patient outcomes.
This review may help when a patient develops persistent diarrhea and weight loss after returning to a local healthcare facility, once intensive monitoring immediately after CAR-T infusion has ended. Sharing the infusion date and treatment details may help local clinicians, hematology-oncology teams, and gastroenterology teams consider delayed enterocolitis together. Even when an infection is identified, persistent symptoms after adequate treatment can prompt reassessment of the cause and discussion of whether upper gastrointestinal endoscopy and duodenal biopsy are warranted, given the possibility of small-bowel involvement. These approaches, however, are the authors’ proposals based on limited clinical data. The review does not establish that early use of any particular drug prevents perforation or sepsis or improves survival.